Rhythm Pharmaceuticals (RYTM) Operating Income: 2020-2025
Historic Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$52.7 million.
- Rhythm Pharmaceuticals' Operating Income fell 19.98% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 29.87%. This contributed to the annual value of -$265.5 million for FY2024, which is 44.02% down from last year.
- Rhythm Pharmaceuticals' Operating Income amounted to -$52.7 million in Q3 2025, which was down 16.24% from -$45.3 million recorded in Q2 2025.
- In the past 5 years, Rhythm Pharmaceuticals' Operating Income registered a high of -$34.4 million during Q1 2021, and its lowest value of -$139.9 million during Q1 2024.
- Moreover, its 3-year median value for Operating Income was -$45.3 million (2025), whereas its average is -$54.1 million.
- In the last 5 years, Rhythm Pharmaceuticals' Operating Income plummeted by 166.29% in 2024 and then surged by 66.40% in 2025.
- Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Operating Income stood at -$51.0 million in 2021, then rose by 17.43% to -$42.1 million in 2022, then increased by 1.99% to -$41.3 million in 2023, then rose by 0.02% to -$41.3 million in 2024, then fell by 19.98% to -$52.7 million in 2025.
- Its last three reported values are -$52.7 million in Q3 2025, -$45.3 million for Q2 2025, and -$47.0 million during Q1 2025.